SE463804B - En anvaendningsklar farmaceutisk komposition av vinkadimerasalter - Google Patents
En anvaendningsklar farmaceutisk komposition av vinkadimerasalterInfo
- Publication number
- SE463804B SE463804B SE8304009A SE8304009A SE463804B SE 463804 B SE463804 B SE 463804B SE 8304009 A SE8304009 A SE 8304009A SE 8304009 A SE8304009 A SE 8304009A SE 463804 B SE463804 B SE 463804B
- Authority
- SE
- Sweden
- Prior art keywords
- solution
- composition according
- sulphate
- mannitol
- per
- Prior art date
Links
- 150000003839 salts Chemical class 0.000 title claims description 6
- 239000008194 pharmaceutical composition Substances 0.000 title claims description 3
- 239000000243 solution Substances 0.000 claims description 53
- LXCFILQKKLGQFO-UHFFFAOYSA-N methylparaben Chemical group COC(=O)C1=CC=C(O)C=C1 LXCFILQKKLGQFO-UHFFFAOYSA-N 0.000 claims description 24
- QELSKZZBTMNZEB-UHFFFAOYSA-N propylparaben Chemical compound CCCOC(=O)C1=CC=C(O)C=C1 QELSKZZBTMNZEB-UHFFFAOYSA-N 0.000 claims description 24
- 239000000203 mixture Substances 0.000 claims description 22
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 claims description 13
- 229930195725 Mannitol Natural products 0.000 claims description 13
- 239000000594 mannitol Substances 0.000 claims description 13
- 235000010355 mannitol Nutrition 0.000 claims description 13
- 239000003755 preservative agent Substances 0.000 claims description 13
- 239000004292 methyl p-hydroxybenzoate Substances 0.000 claims description 12
- 235000010270 methyl p-hydroxybenzoate Nutrition 0.000 claims description 12
- 229960002216 methylparaben Drugs 0.000 claims description 12
- 239000004405 propyl p-hydroxybenzoate Substances 0.000 claims description 12
- 235000010232 propyl p-hydroxybenzoate Nutrition 0.000 claims description 12
- 229960003415 propylparaben Drugs 0.000 claims description 12
- AQTQHPDCURKLKT-JKDPCDLQSA-N vincristine sulfate Chemical compound OS(O)(=O)=O.C([C@@H](C[C@]1(C(=O)OC)C=2C(=CC3=C([C@]45[C@H]([C@@]([C@H](OC(C)=O)[C@]6(CC)C=CCN([C@H]56)CC4)(O)C(=O)OC)N3C=O)C=2)OC)C[C@@](C2)(O)CC)N2CCC2=C1NC1=CC=CC=C21 AQTQHPDCURKLKT-JKDPCDLQSA-N 0.000 claims description 10
- QAOWNCQODCNURD-UHFFFAOYSA-L Sulfate Chemical compound [O-]S([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-L 0.000 claims description 9
- 230000002335 preservative effect Effects 0.000 claims description 9
- 229960003048 vinblastine Drugs 0.000 claims description 9
- JXLYSJRDGCGARV-CFWMRBGOSA-N vinblastine Chemical class C([C@H](C[C@]1(C(=O)OC)C=2C(=CC3=C([C@]45[C@H]([C@@]([C@H](OC(C)=O)[C@]6(CC)C=CCN([C@H]56)CC4)(O)C(=O)OC)N3C)C=2)OC)C[C@@](C2)(O)CC)N2CCC2=C1NC1=CC=CC=C21 JXLYSJRDGCGARV-CFWMRBGOSA-N 0.000 claims description 9
- 229960004528 vincristine Drugs 0.000 claims description 9
- OGWKCGZFUXNPDA-XQKSVPLYSA-N vincristine Chemical class C([N@]1C[C@@H](C[C@]2(C(=O)OC)C=3C(=CC4=C([C@]56[C@H]([C@@]([C@H](OC(C)=O)[C@]7(CC)C=CCN([C@H]67)CC5)(O)C(=O)OC)N4C=O)C=3)OC)C[C@@](C1)(O)CC)CC1=C2NC2=CC=CC=C12 OGWKCGZFUXNPDA-XQKSVPLYSA-N 0.000 claims description 9
- OGWKCGZFUXNPDA-UHFFFAOYSA-N vincristine Natural products C1C(CC)(O)CC(CC2(C(=O)OC)C=3C(=CC4=C(C56C(C(C(OC(C)=O)C7(CC)C=CCN(C67)CC5)(O)C(=O)OC)N4C=O)C=3)OC)CN1CCC1=C2NC2=CC=CC=C12 OGWKCGZFUXNPDA-UHFFFAOYSA-N 0.000 claims description 9
- 229920005862 polyol Polymers 0.000 claims description 8
- 150000003077 polyols Chemical class 0.000 claims description 8
- 229910021653 sulphate ion Inorganic materials 0.000 claims description 8
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 7
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 claims description 6
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 claims description 6
- 239000008351 acetate buffer Substances 0.000 claims description 6
- 239000008101 lactose Substances 0.000 claims description 6
- JXLYSJRDGCGARV-WWYNWVTFSA-N Vinblastine Chemical class O=C(O[C@H]1[C@](O)(C(=O)OC)[C@@H]2N(C)c3c(cc(c(OC)c3)[C@]3(C(=O)OC)c4[nH]c5c(c4CCN4C[C@](O)(CC)C[C@H](C3)C4)cccc5)[C@@]32[C@H]2[C@@]1(CC)C=CCN2CC3)C JXLYSJRDGCGARV-WWYNWVTFSA-N 0.000 claims description 5
- 235000000346 sugar Nutrition 0.000 claims description 4
- NDMPLJNOPCLANR-UHFFFAOYSA-N 3,4-dihydroxy-15-(4-hydroxy-18-methoxycarbonyl-5,18-seco-ibogamin-18-yl)-16-methoxy-1-methyl-6,7-didehydro-aspidospermidine-3-carboxylic acid methyl ester Chemical class C1C(CC)(O)CC(CC2(C(=O)OC)C=3C(=CC4=C(C56C(C(C(O)C7(CC)C=CCN(C67)CC5)(O)C(=O)OC)N4C)C=3)OC)CN1CCC1=C2NC2=CC=CC=C12 NDMPLJNOPCLANR-UHFFFAOYSA-N 0.000 claims description 2
- 229960004355 vindesine Drugs 0.000 claims description 2
- UGGWPQSBPIFKDZ-KOTLKJBCSA-N vindesine Chemical class C([C@@H](C[C@]1(C(=O)OC)C=2C(=CC3=C([C@]45[C@H]([C@@]([C@H](O)[C@]6(CC)C=CCN([C@H]56)CC4)(O)C(N)=O)N3C)C=2)OC)C[C@@](C2)(O)CC)N2CCC2=C1N=C1[C]2C=CC=C1 UGGWPQSBPIFKDZ-KOTLKJBCSA-N 0.000 claims description 2
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 21
- 230000000174 oncolytic effect Effects 0.000 description 6
- 229930013930 alkaloid Natural products 0.000 description 4
- 150000001875 compounds Chemical class 0.000 description 4
- 238000002360 preparation method Methods 0.000 description 4
- WVDDGKGOMKODPV-UHFFFAOYSA-N Benzyl alcohol Chemical compound OCC1=CC=CC=C1 WVDDGKGOMKODPV-UHFFFAOYSA-N 0.000 description 3
- VMHLLURERBWHNL-UHFFFAOYSA-M Sodium acetate Chemical compound [Na+].CC([O-])=O VMHLLURERBWHNL-UHFFFAOYSA-M 0.000 description 3
- 239000000872 buffer Substances 0.000 description 3
- 238000001914 filtration Methods 0.000 description 3
- 239000001632 sodium acetate Substances 0.000 description 3
- 235000017281 sodium acetate Nutrition 0.000 description 3
- VEXZGXHMUGYJMC-UHFFFAOYSA-M Chloride anion Chemical compound [Cl-] VEXZGXHMUGYJMC-UHFFFAOYSA-M 0.000 description 2
- 206010028980 Neoplasm Diseases 0.000 description 2
- ISWSIDIOOBJBQZ-UHFFFAOYSA-N Phenol Chemical compound OC1=CC=CC=C1 ISWSIDIOOBJBQZ-UHFFFAOYSA-N 0.000 description 2
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 2
- 201000011510 cancer Diseases 0.000 description 2
- 239000003795 chemical substances by application Substances 0.000 description 2
- 230000001627 detrimental effect Effects 0.000 description 2
- 239000011521 glass Substances 0.000 description 2
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 description 2
- 239000007788 liquid Substances 0.000 description 2
- RLSSMJSEOOYNOY-UHFFFAOYSA-N m-cresol Chemical compound CC1=CC=CC(O)=C1 RLSSMJSEOOYNOY-UHFFFAOYSA-N 0.000 description 2
- 239000000463 material Substances 0.000 description 2
- 230000001954 sterilising effect Effects 0.000 description 2
- 238000004659 sterilization and disinfection Methods 0.000 description 2
- 150000008163 sugars Chemical class 0.000 description 2
- 150000003467 sulfuric acid derivatives Chemical class 0.000 description 2
- KDQAABAKXDWYSZ-PNYVAJAMSA-N vinblastine sulfate Chemical compound OS(O)(=O)=O.C([C@H](C[C@]1(C(=O)OC)C=2C(=CC3=C([C@]45[C@H]([C@@]([C@H](OC(C)=O)[C@]6(CC)C=CCN([C@H]56)CC4)(O)C(=O)OC)N3C)C=2)OC)C[C@@](C2)(O)CC)N2CCC2=C1NC1=CC=CC=C21 KDQAABAKXDWYSZ-PNYVAJAMSA-N 0.000 description 2
- 229960004982 vinblastine sulfate Drugs 0.000 description 2
- 229960002110 vincristine sulfate Drugs 0.000 description 2
- QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 description 1
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 1
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 1
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 1
- 102000004877 Insulin Human genes 0.000 description 1
- 108090001061 Insulin Proteins 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
- 229930006000 Sucrose Natural products 0.000 description 1
- 229920006362 Teflon® Polymers 0.000 description 1
- 229940122803 Vinca alkaloid Drugs 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 238000003915 air pollution Methods 0.000 description 1
- 239000003513 alkali Substances 0.000 description 1
- 150000003797 alkaloid derivatives Chemical class 0.000 description 1
- 235000019445 benzyl alcohol Nutrition 0.000 description 1
- 239000007853 buffer solution Substances 0.000 description 1
- 229920005549 butyl rubber Polymers 0.000 description 1
- 230000015556 catabolic process Effects 0.000 description 1
- 238000002512 chemotherapy Methods 0.000 description 1
- 238000000354 decomposition reaction Methods 0.000 description 1
- 238000006731 degradation reaction Methods 0.000 description 1
- 239000003085 diluting agent Substances 0.000 description 1
- 239000000539 dimer Substances 0.000 description 1
- 229910001873 dinitrogen Inorganic materials 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 230000000694 effects Effects 0.000 description 1
- 238000004128 high performance liquid chromatography Methods 0.000 description 1
- 239000011261 inert gas Substances 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 229940125396 insulin Drugs 0.000 description 1
- 238000010253 intravenous injection Methods 0.000 description 1
- 238000002386 leaching Methods 0.000 description 1
- 229940126601 medicinal product Drugs 0.000 description 1
- 238000000034 method Methods 0.000 description 1
- 244000005700 microbiome Species 0.000 description 1
- WVDDGKGOMKODPV-ZQBYOMGUSA-N phenyl(114C)methanol Chemical compound O[14CH2]C1=CC=CC=C1 WVDDGKGOMKODPV-ZQBYOMGUSA-N 0.000 description 1
- 125000002467 phosphate group Chemical class [H]OP(=O)(O[H])O[*] 0.000 description 1
- -1 polytetrafluoroethylene Polymers 0.000 description 1
- 229920001343 polytetrafluoroethylene Polymers 0.000 description 1
- 239000004810 polytetrafluoroethylene Substances 0.000 description 1
- 239000002244 precipitate Substances 0.000 description 1
- 229940071643 prefilled syringe Drugs 0.000 description 1
- 230000000717 retained effect Effects 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- 239000000600 sorbitol Substances 0.000 description 1
- 235000010356 sorbitol Nutrition 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 239000005720 sucrose Substances 0.000 description 1
- 238000004809 thin layer chromatography Methods 0.000 description 1
- 231100000816 toxic dose Toxicity 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/475—Quinolines; Isoquinolines having an indole ring, e.g. yohimbine, reserpine, strychnine, vinblastine
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US39965482A | 1982-07-19 | 1982-07-19 | |
| US47607783A | 1983-03-17 | 1983-03-17 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| SE8304009D0 SE8304009D0 (sv) | 1983-07-15 |
| SE8304009L SE8304009L (sv) | 1984-01-20 |
| SE463804B true SE463804B (sv) | 1991-01-28 |
Family
ID=27016716
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SE8304009A SE463804B (sv) | 1982-07-19 | 1983-07-15 | En anvaendningsklar farmaceutisk komposition av vinkadimerasalter |
Country Status (16)
Families Citing this family (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| HU195513B (en) * | 1984-10-16 | 1988-05-30 | Richter Gedeon Vegyeszet | Process for producing stable solutions of alkaloides with bis-indole skeleton |
| FR2597750B1 (fr) * | 1986-04-25 | 1989-06-02 | Pf Medicament | Solution aqueuse stable de sulfate de vincristine |
| FR2623089B1 (fr) * | 1987-11-13 | 1990-04-27 | Pf Medicament | Composition pharmaceutique pour l'administration parenterale de navelbine |
| US4923876A (en) * | 1988-04-18 | 1990-05-08 | Cetus Corporation | Vinca alkaloid pharmaceutical compositions |
| HU204995B (en) * | 1989-11-07 | 1992-03-30 | Richter Gedeon Vegyeszet | Process for producing pharmaceutical composition comprising alkaloid with bis-indole skeleton, with antitumour activity and suitable fr parenteral purposes |
| FR2910812B1 (fr) * | 2006-12-29 | 2009-03-20 | Pierre Fabre Medicament Sa | Compositions pharmaceutiques injectables lyophilisees de derives hemi-synthetiques d'alcaloide de vinca stables a temperature ambiante |
| US11058679B2 (en) | 2015-08-01 | 2021-07-13 | Sun Pharmaceutical Industries Ltd. | Dosage form of vinca alkaloid drug |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3097137A (en) * | 1960-05-19 | 1963-07-09 | Canadian Patents Dev | Vincaleukoblastine |
| US3749784A (en) * | 1972-05-03 | 1973-07-31 | Lilly Co Eli | Psoriasis treatment |
| GB2020180B (en) * | 1978-05-08 | 1982-08-25 | Nelson Res & Dev | Ophthalmic compositions containingcolchicine or vinblastinr |
| US4208414A (en) * | 1978-06-05 | 1980-06-17 | Eli Lilly And Company | Vinblastine in rheumatoid arthritis |
| US4259242A (en) * | 1978-10-10 | 1981-03-31 | Eli Lilly And Company | Method of preparing vindesine sulfate |
| HU181940B (en) * | 1979-11-02 | 1983-11-28 | Richter Gedeon Vegyeszet | Process for producing solutions of vincane derivatives for parentheral application |
| OA06421A (fr) * | 1980-06-10 | 1981-09-30 | Omnium Chimique Sa | Procédé de préparation de dérivés N-(vinblastinoyl-23) d'acides aminés et de peptides. |
-
1983
- 1983-06-15 IT IT21644/83A patent/IT1170152B/it active
- 1983-07-11 DE DE19833324964 patent/DE3324964A1/de active Granted
- 1983-07-11 CH CH3808/83A patent/CH654744A5/de not_active IP Right Cessation
- 1983-07-12 NZ NZ204868A patent/NZ204868A/en unknown
- 1983-07-12 FR FR8311595A patent/FR2531860B1/fr not_active Expired
- 1983-07-12 IL IL69203A patent/IL69203A/xx not_active IP Right Cessation
- 1983-07-13 PH PH29226A patent/PH19098A/en unknown
- 1983-07-13 LU LU84910A patent/LU84910A1/fr unknown
- 1983-07-13 BE BE0/211170A patent/BE897280A/fr unknown
- 1983-07-15 IE IE1646/83A patent/IE55388B1/en not_active IP Right Cessation
- 1983-07-15 AU AU16891/83A patent/AU553514B2/en not_active Expired
- 1983-07-15 SE SE8304009A patent/SE463804B/sv not_active IP Right Cessation
- 1983-07-15 HU HU832522A patent/HU191538B/hu unknown
- 1983-07-15 NL NLAANVRAGE8302552,A patent/NL184146C/xx not_active IP Right Cessation
- 1983-07-15 GB GB08319146A patent/GB2125292B/en not_active Expired
-
1987
- 1987-05-28 HK HK430/87A patent/HK43087A/xx not_active IP Right Cessation
Also Published As
| Publication number | Publication date |
|---|---|
| FR2531860B1 (fr) | 1986-09-26 |
| IL69203A (en) | 1986-03-31 |
| FR2531860A1 (fr) | 1984-02-24 |
| NL184146B (nl) | 1988-12-01 |
| NZ204868A (en) | 1986-10-08 |
| SE8304009D0 (sv) | 1983-07-15 |
| GB2125292B (en) | 1986-06-04 |
| IE831646L (en) | 1984-01-19 |
| NL184146C (nl) | 1989-05-01 |
| DE3324964C2 (enrdf_load_stackoverflow) | 1991-03-14 |
| LU84910A1 (fr) | 1985-04-17 |
| GB2125292A (en) | 1984-03-07 |
| HK43087A (en) | 1987-06-05 |
| GB8319146D0 (en) | 1983-08-17 |
| SE8304009L (sv) | 1984-01-20 |
| BE897280A (fr) | 1984-01-13 |
| NL8302552A (nl) | 1984-02-16 |
| IE55388B1 (en) | 1990-08-29 |
| DE3324964A1 (de) | 1984-01-19 |
| IL69203A0 (en) | 1983-11-30 |
| IT8321644A0 (it) | 1983-06-15 |
| IT1170152B (it) | 1987-06-03 |
| CH654744A5 (de) | 1986-03-14 |
| HU191538B (en) | 1987-03-30 |
| AU553514B2 (en) | 1986-07-17 |
| AU1689183A (en) | 1984-01-26 |
| PH19098A (en) | 1986-01-02 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| NZ501382A (en) | Stable insulin formulations comprising a non-phosphate buffer | |
| KR101716215B1 (ko) | 즉시 주입가능한 젬시타빈 용액 | |
| US11813291B2 (en) | Ready-to-use potassium phosphates in sodium chloride solutions | |
| NO336427B1 (no) | Farmasøytisk sammensetning av vinflunin som er ment for parenteral administrering, fremstillingsmåte og anvendelse derav | |
| US4619935A (en) | Stable oncolytic formulations | |
| EP1283051B1 (en) | Stable insulin formulations | |
| SE463804B (sv) | En anvaendningsklar farmaceutisk komposition av vinkadimerasalter | |
| CN111494611A (zh) | 一种卡式瓶多剂量笔式注射组合包装的干扰素注射液 | |
| CN116172953A (zh) | 一种低浓度的舒更葡糖注射液 | |
| EP2887953B1 (en) | Improved daptomycin injectable formulation | |
| AU777397B2 (en) | Multi-dose erythropoietin formulations | |
| WO2025126235A1 (en) | Ready to use injectable formulation of potassium phosphate | |
| US11925661B2 (en) | Ready-to-use potassium phosphates in sodium chloride solutions | |
| JPS5929617A (ja) | ビンカ・アルカロイド製剤 | |
| US12115187B1 (en) | Ready-to-use sodium phosphates injection | |
| US12268825B1 (en) | Ready-to-use sodium phosphates injection | |
| US20230233453A1 (en) | Suxamethonium composition and prefilled syringe thereof | |
| CN114617844A (zh) | 一种盐酸多巴酚丁胺水针注射液的制备方法 | |
| WO2024100679A1 (en) | Parenteral formulations of flucytosine | |
| WO2021234094A1 (en) | Ceftriaxone compositions with magnesium component | |
| WO1985003202A1 (en) | Terminally sterilizable isotonic drug compositions | |
| HK1116419A (en) | Multi-dose erythropoietin formulations | |
| CN114053397A (zh) | 一种稳定的干扰素多剂量注射液及其制备方法 | |
| CA2001643A1 (en) | Preservative-free multi-dose vincristine solution | |
| SK286990B6 (sk) | Viacdávková kompozícia na báze erytropoetínu |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| NAL | Patent in force |
Ref document number: 8304009-7 Format of ref document f/p: F |
|
| NUG | Patent has lapsed |